LANDOS BIOPHARMA INC (LABP) Stock Price, Quote, News and Overview
NASDAQ:LABP - Nasdaq - US5150692011 - Common Stock - Currency: USD
LABP Quote, Performance and Key Statistics
22.93
+0.13 (+0.58%)
The current stock price of LABP is 22.93 USD. In the past month the price increased by 1.96%. In the past year, price increased by 693.43%.
LABP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About LABP
Company Profile
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. The company is headquartered in Blacksburg, Virginia and currently employs 22 full-time employees. The company went IPO on 2021-02-04. The company is engaged in the clinical development of compounds that target pathways at the interface of immunity and metabolism. Its lead candidate is NX-13, an oral, gut-selective NLRX1 agonist. The company is developing NX-13 as a once-daily oral treatment for ulcerative colitis (UC) that targets the NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines in UC. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. In addition to NX-13, it has discovered several preclinical product candidates, such as LABP-73, LABP-66 and LABP-69. LABP-73, an oral, small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.
Company Info
LANDOS BIOPHARMA INC
1800 Kraft Drive, Suite 216
Blacksburg VIRGINIA 24060 US
CEO: Josep Bassaganya-Riera
Employees: 22
Company Website: https://www.landosbiopharma.com/
Phone: 15408182844
LANDOS BIOPHARMA INC / LABP FAQ
What is the stock price of LANDOS BIOPHARMA INC today?
The current stock price of LABP is 22.93 USD. The price increased by 0.58% in the last trading session.
What is the ticker symbol for LANDOS BIOPHARMA INC stock?
The exchange symbol of LANDOS BIOPHARMA INC is LABP and it is listed on the Nasdaq exchange.
On which exchange is LABP stock listed?
LABP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LANDOS BIOPHARMA INC stock?
8 analysts have analysed LABP and the average price target is 12.96 USD. This implies a price decrease of -43.46% is expected in the next year compared to the current price of 22.93. Check the LANDOS BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LANDOS BIOPHARMA INC worth?
LANDOS BIOPHARMA INC (LABP) has a market capitalization of 71.77M USD. This makes LABP a Micro Cap stock.
How many employees does LANDOS BIOPHARMA INC have?
LANDOS BIOPHARMA INC (LABP) currently has 22 employees.
What are the support and resistance levels for LANDOS BIOPHARMA INC (LABP) stock?
LANDOS BIOPHARMA INC (LABP) has a support level at 22.43 and a resistance level at 22.94. Check the full technical report for a detailed analysis of LABP support and resistance levels.
Should I buy LANDOS BIOPHARMA INC (LABP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LABP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LABP, evaluating the profitability, health, valuation and growth aspects
- LANDOS BIOPHARMA INC (LABP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LANDOS BIOPHARMA INC (LABP) Sales and EPS estimates to see what analysts future expectations are.
- LANDOS BIOPHARMA INC (LABP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LANDOS BIOPHARMA INC (LABP) Insider and Institutional Ownership to learn about the owners and their transactions.
- LANDOS BIOPHARMA INC (LABP) Stock Chart to make your own analysis
- LANDOS BIOPHARMA INC (LABP) Latest news and press-releases to stay up to date.
Does LANDOS BIOPHARMA INC (LABP) stock pay dividends?
LABP does not pay a dividend.
When does LANDOS BIOPHARMA INC (LABP) report earnings?
LANDOS BIOPHARMA INC (LABP) will report earnings on 2024-08-07, before the market open.
What is the Price/Earnings (PE) ratio of LANDOS BIOPHARMA INC (LABP)?
LANDOS BIOPHARMA INC (LABP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.99).
LABP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LABP. When comparing the yearly performance of all stocks, LABP is one of the better performing stocks in the market, outperforming 99.88% of all stocks.
LABP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LABP. While LABP has a great health rating, there are worries on its profitability.
LABP Financial Highlights
Over the last trailing twelve months LABP reported a non-GAAP Earnings per Share(EPS) of -3.99. The EPS increased by 43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.94% | ||
| ROE | -107.09% | ||
| Debt/Equity | 0 |
LABP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to LABP. The Buy consensus is the average rating of analysts ratings from 8 analysts.